A Phase I Dose-escalation Study of VEGF-Antisense Oligonucleotide (VEGF-AS) in Patients with Advanced Malignancies.

Trial Profile

A Phase I Dose-escalation Study of VEGF-Antisense Oligonucleotide (VEGF-AS) in Patients with Advanced Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2006

At a glance

  • Drugs Veglin (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Oct 2004 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top